You are here

Article Text

Article menu

Download PDFPDF

Section 6: Education and research
6ER-026 Spectrum of heart failure in 16 sub-Saharan African countries: treatments and in-hospital outcome
Free
  1. P Cavagna1,
  2. C Kouam Kouam2,
  3. IB Diop3,
  4. E Limbole4,
  5. L Allawaye5,
  6. JL Takombe4,
  7. AK Traore6,
  8. R N’Guetta7,
  9. MS Ikama8,
  10. X Jouven9,
  11. M Antignac1
  1. 1Pitie Salpetriere Aphp University Hospital, Pharmacy, Paris, France
  2. 2Regional Hospital of Bafoussam, Cardiology, Bafoussam, Cameroon
  3. 3Fann Universitary Hospital, Cardiology, Dakar, Senegal
  4. 4Ngaliema Hospital, Cardiology, Kinshasa, Congo Republic Of
  5. 5Hopital General de la Reference Nationale, Cardiology, Ndjamena, Chad
  6. 6Hospital of Sikasso, Cardiology, Sikasso, Mali
  7. 7Abidjan Institute of Cardiology, Cardiology, Abidjan, Cote D’ivoire
  8. 8National University Hospital of Brazzaville, National University Hospital of Brazzaville, Brazzaville, Congo Brazzaville
  9. 9European Georges Pompidou Hospital- Ap-Hp Centre- University of Paris, Cardiology, Paris, France

Abstract

Background and Importance Heart failure (HF) is the most common primary diagnosis for patients admitted to hospital with heart disease in sub-Saharan Africa (SSA). However, little is known about the management of HF in hospitalisation in SSA.

Aim and Objectives To describe in hospital drugs strategies to manage HF in 36 cardiovascular (CV) departments.

Material and Methods We conducted a transversal and longitudinal study in CV departments of 36 hospital (public and private) in 16 SSA countries. The February study is an ongoing observatory included all inpatients in February from each year since 2016. Data including socio-demographic and clinical characteristics, CV risk factors, causes of admission, medication and length of stay were collected during hospitalisation by physicians. Patient wealth index was assessed by physicians as low, middle and high according to patient capacity to afford hospitalisation. All analyses were performed with random effect on countries and through scripts developed in the R software 4.0.3.

Results Overall, 2084 patients were admitted for HF in the February study. HF representing 47.9% of all patients included. The mean age was 57 ± 17.4 years and 53.8% were men. Proportions of patients admitted for HF varied across countries from 21.4% in Burundi to 66% in Congo (p<0.01). Average length of stay in hospitals was 11 days and mortality rate was 13%. Among HF patients, 74% of patients had CV risk factors and hypertension was reported in 55.8% of patients. During hospitalisation, 88.8% of patients were treated with diuretics followed by angiotensin-converting enzyme inhibitors (ACEI) (61.8%), anticoagulant (47.8%) and beta blockers (BB) (34.6%) (figure). Monotherapy were used in 14%, combination of two drugs, three drugs and four drugs strategies were used in 35%, 33% 12% respectively. Diuretics were mostly prescribed in patient with low wealth index whereas ACEI, BB and anticoagulant in high wealth index (p<0.05).

Abstract 6ER-026 Figure 1
Abstract 6ER-026 Figure 1

Conclusion and Relevance HF treatment access varied significantly across countries and according to patient wealth index.

Conflict of Interest No conflict of interest.

https://doi.org/10.1136/ejhpharm-2023-eahp.349

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.